- Home
- CVR vs APRE Comparison
CVR vs APRE Comparison
Compare CVR & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- APRE
- Stock Information
- Founded
- CVR 1920
- APRE 2006
- Country
- CVR United States
- APRE United States
- Employees
- CVR N/A
- APRE N/A
- Industry
- CVR Industrial Machinery/Components
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CVR Industrials
- APRE Health Care
- Exchange
- CVR Nasdaq
- APRE Nasdaq
- Market Cap
- CVR 11.1M
- APRE 10.0M
- IPO Year
- CVR N/A
- APRE 2019
- Fundamental
- Price
- CVR $12.12
- APRE $1.70
- Analyst Decision
- CVR
- APRE Strong Buy
- Analyst Count
- CVR 0
- APRE 2
- Target Price
- CVR N/A
- APRE $15.50
- AVG Volume (30 Days)
- CVR 4.2K
- APRE 56.7K
- Earning Date
- CVR 08-12-2025
- APRE 08-11-2025
- Dividend Yield
- CVR 0.99%
- APRE N/A
- EPS Growth
- CVR N/A
- APRE N/A
- EPS
- CVR N/A
- APRE N/A
- Revenue
- CVR $26,379,081.00
- APRE $1,284,475.00
- Revenue This Year
- CVR N/A
- APRE N/A
- Revenue Next Year
- CVR N/A
- APRE N/A
- P/E Ratio
- CVR N/A
- APRE N/A
- Revenue Growth
- CVR N/A
- APRE 33.27
- 52 Week Low
- CVR $8.15
- APRE $1.41
- 52 Week High
- CVR $22.27
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- CVR 46.01
- APRE 46.90
- Support Level
- CVR $12.04
- APRE $1.60
- Resistance Level
- CVR $12.49
- APRE $1.97
- Average True Range (ATR)
- CVR 0.57
- APRE 0.16
- MACD
- CVR -0.06
- APRE 0.00
- Stochastic Oscillator
- CVR 30.00
- APRE 44.99
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.